Edwards Lifesciences Corp.’s Sapien M3 secured CE mark for its Sapien M3 mitral valve replacement system for transfemoral treatment of patients with mitral valve disease who are ineligible for surgery ...

Edwards Lifesciences has received CE marking for its transfemoral transcatheter mitral valve replacement system, setting up ...

Edwards Lifesciences (NYSE:EW) announced today that it received CE mark approval for its Sapien M3 mitral valve replacement ...

South Jordan, Utah-based Merit adds the latest delivery system to its growing electrophysiology (EP) and cardiac rhythm ...

The Cardiac Dimensions Carillon Mitral Contour System is a minimally invasive mitral regurgitation therapy made possible by ...

The “passive” notification led to more patients with severe AS undergoing valve replacement, but more can be done still.

The DapaTAVI trial assessed the benefits of dapagliflozin in patients discharged after TAVI with a history of heart failure plus 1 of the following comorbidities: LVEF ≤40%, diabetes, or renal ...

Champions of tricuspid transcatheter edge-to-edge repair (TEER) were buoyed by 2-year results of the TRILUMINATE trial ...

Patients who underwent transcatheter aortic valve replacement (TAVR) with a valve designed to treat aortic regurgitation had an overall mortality rate of just 8.1% at one year, well below the trial’s ...

Get Instant Summarized Text (Gist) A new transcatheter valve, the Trilogy system, has demonstrated safety and efficacy in treating aortic regurgitation, with a one-year mortality rate of 8.1% ...

Severe mitral regurgitation (MR) also causes a low-flow state ... Data from an institutional echo database identified 1189 patients with adjudicated severe aortic stenosis (aortic valve area ≤1.0 cm 2 ...